18F-FDG PET for Measurement of Response and Prediction of Outcome to Relapsed or Refractory Mantle Cell Lymphoma Therapy with Bendamustine-Rituximab.

MLA

Lamonica, Dominick, et al. “18F-FDG PET for Measurement of Response and Prediction of Outcome to Relapsed or Refractory Mantle Cell Lymphoma Therapy with Bendamustine-Rituximab.” Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, vol. 58, no. 1, Jan. 2017, pp. 62–68. EBSCOhost, https://doi.org/10.2967/jnumed.116.173542.

APA

Lamonica, D., Graf, D. A., Munteanu, M. C., & Czuczman, M. S. (2017). 18F-FDG PET for Measurement of Response and Prediction of Outcome to Relapsed or Refractory Mantle Cell Lymphoma Therapy with Bendamustine-Rituximab. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 58(1), 62–68. https://doi.org/10.2967/jnumed.116.173542

Chicago

Lamonica, Dominick, Daniel A Graf, Mihaela C Munteanu, and Myron S Czuczman. 2017. “18F-FDG PET for Measurement of Response and Prediction of Outcome to Relapsed or Refractory Mantle Cell Lymphoma Therapy with Bendamustine-Rituximab.” Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine 58 (1): 62–68. doi:10.2967/jnumed.116.173542.